Kac and New Determinants for Fractional Superconformal Algebras

We derive the Kac and new determinant formulae for an arbitrary (integer) level $K$ fractional superconformal algebra using the BRST cohomology techniques developed in conformal field theory. In particular, we reproduce the Kac determinants for the Virasoro ($K=1$) and superconformal ($K=2$) algebras. For $K\geq3$ there always exist modules where the Kac determinant factorizes into a product of more fundamental new determinants. Using our results for general $K$, we sketch the non-unitarity proof for the $SU(2)$ minimal series; as expected, the only unitary models are those already known from the coset construction. We apply the Kac determinant formulae for the spin-4/3 parafermion current algebra ({\em i.e.}, the $K=4$ fractional superconformal algebra) to the recently constructed three-dimensional flat Minkowski space-time representation of the spin-4/3 fractional superstring. We prove the no-ghost theorem for the space-time bosonic sector of this theory; that is, its physical spectrum is free of negative-norm states.Comment: 33 pages, Revtex 3.0, Cornell preprint CLNS 93/124

First-order formalism and dark energy

This work deals with cosmological models driven by real scalar field, described by standard dynamics in generic spherical, flat, and hyperbolic geometries. We introduce a first-order formalism, which shows how to relate the potential that specifies the scalar field model to Hubble's parameter in a simple and direct manner. Extensions to tachyonic dynamics, and to two or more real scalar fields are also presented.Comment: 7 pages, 3 figure

Instant preheating mechanism and UHECR

Top-down models assume that the still unexplained Ultra High Energy Cosmic Rays (UHECR's) are the decay products of superheavy particles. Such particles may have been produced by one of the post-inflationary reheating mechanisms and may account for a fraction of the cold dark matter. In this paper, we assess the phenomenological applicability of the simplest instant preheating framework not to describe a reheating process, but as a mechanism to generate relic supermassive particles as possible sources of UHECR's. We use cosmic ray flux and cold dark matter observational data to constrain the parameters of the model.Comment: 7 pages, 2 figures, submitted to PR

BRST Analysis of Physical States for 2D (Super) Gravity Coupled to (Super) Conformal Matter

We summarize some recent results on the BRST analysis of physical states of 2D gravity coupled to c<=1 conformal matter and the supersymmetric generalization.Comment: 11 page

Oral and intravenous methadone use: some clinical and pharmacokinetic aspects.

A sample of 15 patients participating in an injectable methadone trial and of 15 patients in an oral methadone maintenance treatment, who admitted injecting part or all of their methadone take-home doses, were compared to 20 patients in maintenance treatment who use methadone exclusively by mouth. The present study confirms the poorer general health, the higher levels of emotional, psychological or psychiatric problems, the higher use of illicit drugs, and the higher number of problems related to employment and support associated with the use of the intravenous mode of administration of methadone. As expected, due to the shunt of metabolism in the gut wall and of the liver first-pass effect, higher concentration to dose ratios of (R)-methadone, which is the active enantiomer, were measured in the intravenous group (23% increase). This difference reached an almost statistically significant value (P = 0.054). This raises the question whether the effect of a higher methadone dose could be unconsciously sought by some of the intravenous methadone users

Ultrasonic atomization and subsequent polymer desolvation for peptide and protein microencapsulation into biodegradable polyesters.

The determination of in vitro release kinetics of peptides from poly(d,l-lactide-co-glycolide) (PLGA) microspheres generally requires optimization of the test conditions for a given formulation. This is particularly important when in vitro/in vivo correlation should be determined. Here, the somatostatin analogue vapreotide pamoate, an octapeptide, was microencapsulated into PLGA 50:50 by spray-drying. The solubility of this peptide and its in vitro release kinetics from the microspheres were studied in various test media. The solubility of vapreotide pamoate was approximately 20–40 μg/ml in 67 mM phosphate buffer saline (PBS) at pH 7.4, but increased to approximately 500–1000 μg/ml at a pH of 3.5. At low pH, the solubility increased with the buffer concentration (1–66 mM). Very importantly, proteins (aqueous bovine serum albumin (BSA) solution or human serum) appeared to solubilize the peptide pamoate, resulting in solubilities ranging from 900 to 6100 μg/ml. The release rate was also greatly affected by the medium composition. Typically, in PBS of pH 7.4, only 33±1% of the peptide were released within 4 days, whereas 53±2 and 61±0.9% were released in 1% BSA solution and serum, respectively. The type of medium was found critical for the estimation of the in vivo release. The in vivo release kinetics of vapreotide pamoate from PLGA microspheres following administration to rats were qualitatively in good agreement with those obtained in vitro using serum as release medium. Finally, sterilization by γ-irradiation had only a minor effect on the in vivo pharmacokinetics

Ultrasonic atomization and subsequent polymer desolvation for peptide and protein microencapsulation into biodegradable polyesters.

The determination of in vitro release kinetics of peptides from poly(d,l-lactide-co-glycolide) (PLGA) microspheres generally requires optimization of the test conditions for a given formulation. This is particularly important when in vitro/in vivo correlation should be determined. Here, the somatostatin analogue vapreotide pamoate, an octapeptide, was microencapsulated into PLGA 50:50 by spray-drying. The solubility of this peptide and its in vitro release kinetics from the microspheres were studied in various test media. The solubility of vapreotide pamoate was approximately 20–40 μg/ml in 67 mM phosphate buffer saline (PBS) at pH 7.4, but increased to approximately 500–1000 μg/ml at a pH of 3.5. At low pH, the solubility increased with the buffer concentration (1–66 mM). Very importantly, proteins (aqueous bovine serum albumin (BSA) solution or human serum) appeared to solubilize the peptide pamoate, resulting in solubilities ranging from 900 to 6100 μg/ml. The release rate was also greatly affected by the medium composition. Typically, in PBS of pH 7.4, only 33±1% of the peptide were released within 4 days, whereas 53±2 and 61±0.9% were released in 1% BSA solution and serum, respectively. The type of medium was found critical for the estimation of the in vivo release. The in vivo release kinetics of vapreotide pamoate from PLGA microspheres following administration to rats were qualitatively in good agreement with those obtained in vitro using serum as release medium. Finally, sterilization by γ-irradiation had only a minor effect on the in vivo pharmacokinetics